Daniel V.T. Catenacci

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +11

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro, Hyun Cheol Chung, Veena Shankaran et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +8

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Alexa B. Schrock, Ching Ouyang, Jaideep Sandhu et al. · Annals of Oncology · 2019 · 628 citations

Medicine, Immunology, Oncology +17

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison et al. · Journal of Clinical Oncology · 2015 · 544 citations

Medicine, Oncology, Pharmacology +17